GBI Biomanufacturing and Allterum Therapeutics Announce Strategic Collaboration to Manufacture Therapeutic Antibody for Clinical Trials
PLANTATION, Florida and HOUSTON, Texas, Oct. 8, 2024 /PRNewswire/ — GBI Biomanufacturing, a leading Contract Development and Manufacturing Organization (CDMO), and Allterum Therapeutics, a Fannin-Founded Company, are pleased to announce a manufacturing partnership to advance Allterum's lead candidate 4A10 into clinic. 4A10 is a monoclonal antibody (mAb) targeting CD127, a receptor expressed by a broad variety of cancers.